Stifel lowered the firm’s price target on DarioHealth to $6 from $9 and keeps a Buy rating on the shares after the company pre-announced Q2 revenue below consensus and the firm’s estimate. The pre-release appears to have been driven by Aetna’s decision to defer the rollout of their behavioral product embedding the Dario solution to early 2024 and the firm is lowering its 2023/2024 revenue and EBITDA estimates to reflect the Aetna deferral and a pause at Sanofi, but it adds that it expects both relationships to reaccelerate in 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DRIO: